Bristol-Myers Squibb (BMYD) 주식 개요

브리스톨-마이어스 스퀴브 컴퍼니는 전 세계에서 바이오 의약품을 발굴, 개발, 허가, 제조, 마케팅, 유통 및 판매하는 기업입니다. 자세히 보기

BMYD 펀더멘털 분석
스노우플레이크 점수
가치 평가	4/6
미래 성장	1/6
과거 실적	4/6
재무 건전성	3/6
배당	5/6

강점

공정 가치 추정치보다 낮은 32.5% 에서 거래

지난 1년간 수익이 83.8% 증가했습니다.

3.89% 의 안정적인 배당금을 지급합니다.

위험 분석

향후 3년 동안 수익이 연평균 6.9% 감소할 것으로 예상됩니다.

부채비율이 높네요

재무 결과에 영향을 미치는 대규모 일회성 항목

Last Earnings Call

Q2 2026 · 30 Jul 2026

Full Transcript

Bristol-Myers Squibb (BMS) reported a strong Q2 2026, with revenue of $13 billion, a 5% year-over-year increase. The growth portfolio—featuring key assets like Reblozyl, Breyanzi, and Camzyos—rose 14%, now accounting for nearly 60% of total revenue. Eliquis remained a standout, with 21% growth. Due to this first-half momentum, management raised full-year 2026 revenue and adjusted EPS guidance.

Analyst Consensus vs. Actual Results:

Revenue: Consensus estimates were approximately $12.75 billion. BMS beat expectations with $13 billion.
Adjusted EPS: Consensus estimates were $1.98. BMS beat expectations with $2.04.

Management emphasized continued investment in its CELMoD platform (iberdomide, mezigdomide) and highlighted progress in its pipeline, though they noted timing updates for milvexian and the Cobenfy ADEPT program, now expected to read out in 2027.

Market Reaction

Bristol-Myers Squibb’s stock rose by approximately 3.2% on July 30, 2026. Analysts cited the earnings beat, the raised full-year financial guidance, and the robust 14% growth in the company's core "growth portfolio" as primary drivers for the positive investor sentiment.

BMYD Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW481,888 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

481,888 investors already sharing narratives

View all narratives

Bristol-Myers Squibb Company 경쟁사

가격 이력 및 성과

Bristol-Myers Squibb 주가의 최고가, 최저가 및 변동 요약
과거 주가
현재 주가	US$22.50
52주 최고가	US$23.00
52주 최저가	US$14.45
베타	0.23
1개월 변동	13.64%
3개월 변동	14.16%
1년 변동	47.54%
3년 변동	n/a
5년 변동	n/a
IPO 이후 변동	9.22%

최근 뉴스 및 업데이트

Recent updates

주주 수익률

	BMYD	AR Pharmaceuticals	AR 시장
7D	-0.7%	3.0%	-5.0%
1Y	47.5%	29.7%	29.6%

수익률 대 산업: BMYD은 지난 1년 동안 29.7%의 수익을 기록한 AR Pharmaceuticals 산업보다 더 좋은 성과를 냈습니다.

수익률 대 시장: BMYD은 지난 1년 동안 29.6%를 기록한 AR 시장보다 더 좋은 성과를 냈습니다.

주가 변동성

Is BMYD's price volatile compared to industry and market?
BMYD volatility
BMYD Average Weekly Movement	4.8%
Pharmaceuticals Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in AR Market	7.1%
10% least volatile stocks in AR Market	3.1%

안정적인 주가: BMYD는 지난 3개월 동안 AR 시장에 비해 주가 변동성이 크지 않았습니다.

시간에 따른 변동성: BMYD의 주간 변동성(5%)은 지난 1년 동안 안정적이었습니다.

회사 소개

설립	직원 수	CEO	웹사이트
1887	32,500	Chris Boerner	www.bms.com

브리스톨-마이어스 스퀴브 컴퍼니는 전 세계에서 바이오 의약품을 발견, 개발, 허가, 제조, 마케팅, 유통 및 판매하는 회사입니다. 종양학, 혈액학, 면역학, 심혈관, 신경과학 및 기타 분야를 위한 제품을 제공합니다. 주요 제품으로는 비판막성 심방세동 환자의 뇌졸중/전신색전증 위험 감소 및 심부정맥혈전증/폐색전증 치료를 위한 엘리퀴스, 다양한 항암 적응증을 위한 옵디보, 다발성 골수종 치료제 포말리스트/이노비드, 활성 류마티스 관절염 및 건선성 관절염 치료제 오렌시아, 필라델피아 염색체 양성 만성골수성백혈병 환자 치료제 스프라이셀 등이 있습니다.

Bristol-Myers Squibb Company 기초 지표 요약

Bristol-Myers Squibb의 순이익과 매출은 시가총액과 어떻게 비교됩니까?
BMYD 기초 통계
시가총액	US$132.20b
순이익 (TTM)	US$9.28b
매출 (TTM)	US$49.19b

14.2x

주가수익비율(P/E)

2.7x

주가매출비율(P/S)

BMYD는 고평가되어 있습니까?

공정 가치 및 평가 분석 보기

순이익 및 매출

최근 실적 보고서(TTM)의 주요 수익성 지표
BMYD 손익계산서 (TTM)
매출	US$49.19b
매출원가	US$13.94b
총이익	US$35.25b
기타 비용	US$25.97b
순이익	US$9.28b

최근 보고된 실적

Jun 30, 2026

다음 실적 발표일

Oct 29, 2026

주당순이익(EPS)	4.54
총이익률	71.66%
순이익률	18.87%
부채/자본 비율	193.2%

BMYD의 장기 실적은 어땠습니까?

과거 실적 및 비교 보기

배당

3.9%

현재 배당 수익률

55%

배당 성향

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/08/10 19:53
종가	2026/08/07 00:00
수익	2026/06/30
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Bristol-Myers Squibb Company는 45명의 분석가가 다루고 있습니다. 이 중 25명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
David Toung	Argus Research Company
Emily Field	Barclays
Charles Butler	Barclays

Bristol-Myers Squibb (BMYD) 주식 개요

강점

위험 분석

Market Reaction

Join community and earn perks

Bristol-Myers Squibb Company 경쟁사

GSK

Sanofi

Pfizer

Chugai Pharmaceutical

가격 이력 및 성과

최근 뉴스 및 업데이트

AstraZeneca And Bristol Myers Squibb Reportedly Engages In Merger Talks

Bristol Myers Squibb Receives FDA Acceptance for New Drug Application For Mezigdomide in Combination with Carfilzomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

Bristol-Myers Squibb Company(NYSE:BMY) dropped from Russell 3000E Growth Benchmark

Bristol Myers Squibb Declares Quarterly Dividend, Payable on August 3, 2026

Bristol Myers Squibb Announces A Supplemental New Drug Application

Bristol-Myers Squibb Company Presents Positive Phase 3 Results For Mezigdomide In Combination With Carfilzomib And Dexamethasone In Relapsed Or Refractory Multiple Myeloma

Recent updates

AstraZeneca And Bristol Myers Squibb Reportedly Engages In Merger Talks

Bristol Myers Squibb Receives FDA Acceptance for New Drug Application For Mezigdomide in Combination with Carfilzomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

Bristol-Myers Squibb Company(NYSE:BMY) dropped from Russell 3000E Growth Benchmark

Bristol Myers Squibb Declares Quarterly Dividend, Payable on August 3, 2026

Bristol Myers Squibb Announces A Supplemental New Drug Application

Bristol-Myers Squibb Company Presents Positive Phase 3 Results For Mezigdomide In Combination With Carfilzomib And Dexamethasone In Relapsed Or Refractory Multiple Myeloma

Bristol Myers Squibb Unveils New Data Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline

Bristol Myers Squibb Launch Sotyktu Approaches to Tyk2 Adoption

Bristol Myers Squibb Receives European Commission Approval of Sotyktu for the Treatment of Active Psoriatic Arthritis in Adults

Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Bristol Myers Squibb Announces Data from Phase 4 Clinical Trial Evaluating Symptom Stability, Safety and Tolerability of Cobenfy (Xanomeline and Trospium Chloride)

Bristol-Myers Squibb Company, Annual General Meeting, May 05, 2026

Bristol Myers Squibb Presents New Camzyos Data At American College of Cardiology Annual Scientific Session & Expo 2026

Bristol Myers Squibb announces Opdivo (nivolumab) received approval for two new classical Hodgkin Lymphoma (cHL) indications in the U.S. and the European Union

Evotec Se Receives Milestone for Initiation of Clinical Study of Bms-986506 in Collaboration with Bristol Myers Squibb

Bristol-Myers Squibb Company to Report Q1, 2026 Results on Apr 30, 2026

Bristol Myers Squibb Announces Positive Phase 3 Results From Successor-2 Study Of Oral Mezigdomide In Relapsed Or Refractory Multiple Myeloma

Bristol Myers Squibb Receives U.S. FDA Approval For Sotyktu For Treatment Of Adults With Active Psoriatic Arthritis

Bristol Myers Squibb Declares Quarterly Dividend, Payable on May 1, 2026

Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha-Thalassemia

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma

Piramal Critical Care B.V. entered into an agreement to acquire Kenalog Brand of Bristol-Myers Squibb Company (NYSE:BMY) for $100 million.

Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (Mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Amgen Inc. (NasdaqGS:AMGN) acquired Dark Blue Therapeutics Ltd from Oxford Science Enterprises, Bristol-Myers Squibb Company (NYSE:BMY) and Evotec SE (XTRA:EVT) in a transaction valued at $840 million.

Bristol-Myers Squibb Company to Report Q4, 2025 Results on Feb 05, 2026

Bristol Myers Squibb Announces Dividend Increase, Payable on February 2, 2026

Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025

Bristol Myers Squibb's Breyanzi Approves by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)

Bristol Myers Squibb Announces Continuation of Adept-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease

Bristol Myers Squibb Data At Ash 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio

Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma

State of Texas Sues Bristol-Myers Squibb and Sanofi for Deceptive Marketing of Blood Thinner Plavix

Bristol Myers Squibb in Collaboration with Johnson & Johnson Announces Update on Phase 3 Librexia ACS Trial

Bristol-Myers Squibb Company Updates Earnings Guidance for the Year 2025

Bristol Myers Squibb Presents Two Late-Breaking Presentations Demonstrating Sotyktu (Deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus

Systimmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-Bren, an EGFR X HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors At ESMO 2025

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Orbital Therapeutics, Inc. for $1.5 billion.

Bristol Myers Squibb's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer's Disease

Bristol Myers Squibb Builds on Eliquis (apixaban) Direct-To-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu (deucravacitinib)

Bristol-Myers Squibb Company Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma

Bristol-Myers Squibb Company to Report Q3, 2025 Results on Oct 30, 2025

Bristol-Myers Squibb Company Announces Quarterly Dividend, Payable on November 3, 2025

Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (Mavacamten) Across Four Continents at the European Society of Cardiology (ESC) Congress 2025

Systimmune Inc. and Bristol Myers Squibb Announces That the U.S. Food and Drug Administration Has Granted Breakthrough Therapy Designation to Systimmune Inc

Bristol Myers Squibb's Application for Breyanzi (Lisocabtagene Maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)

Bristol Myers Squibb Announces Management Changes

Bristol Myers Squibb's Supplemental New Drug Application for Sotyktu (Deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally

Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia

Bristol-Myers Squibb Company(NYSE:BMY) dropped from Russell 1000 Defensive Index

U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of RemS Programs Within Bristol Myers Squibb's Cell Therapy Labels

Bristol-Myers Squibb Company Announces Quarterly Dividend, Payable on August 1, 2025

Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025

Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA -1 Trial Demonstrating Superiority of Sotyktu (Deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis

Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo®? (nivolumab) Across Multiple Solid Tumor Indications

Bristol Myers Squibb to Present Data at ASCO 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline

Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo®? (Nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with Pd-1 Expression 1%

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of 2seventy bio, Inc. (NasdaqGS:TSVT).

Bristol Myers Squibb Announces Executive Changes

Bristol-Myers Squibb Company Revises Earnings Guidance for the Year 2025

Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia

Bristol Myers Squibb Announces U.S. Food and Drug Administration Updates CAMZYOS®? (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications